Welcome to our dedicated page for Nephros SEC filings (Ticker: NEPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracing revenue from hollow-fiber dialysis filters to commercial ice-machine cartridges, Nephros’s disclosures span both medical-device and water-tech regulations. That dual focus turns a single 10-K into a maze of FDA references, segment margins, and cost-of-goods nuances. If parsing all that feels overwhelming, you’re not alone. Investors often Google “Nephros SEC filings explained simply” or ask, “Where can I find the Nephros quarterly earnings report 10-Q filing?” Stock Titan’s AI is built precisely for that challenge.
Instead of sifting through hundreds of pages, open any form on this page and our platform delivers an instant, plain-English briefing. Need to track “Nephros insider trading Form 4 transactions”? You’ll see alerts within seconds. Curious about liquidity swings? Our AI highlights them in the latest 8-K. For every filing, we outline why it matters:
- 10-K: Nephros annual report 10-K simplified with segment revenue, R&D outlays, and litigation matters.
- 10-Q: Nephros earnings report filing analysis for quarter-over-quarter filter sales and gross margins.
- 8-K: Nephros 8-K material events explained so you notice distributor wins or FDA correspondence right away.
- Form 4: Nephros Form 4 insider transactions real-time shows “Nephros executive stock transactions Form 4” before markets react.
- DEF 14A: Nephros proxy statement executive compensation summarized in one screen.
Whether you’re modeling cartridge reorder velocity or assessing cash burn, understanding Nephros SEC documents with AI turns raw data into context. Real-time feeds, side-by-side comparisons, and keyword search mean you move from download to decision in minutes, not days.
Nephros, Inc. entered a new long-term license and supply agreement with Medica S.p.A. for ultrafiltration products. The deal gives Nephros an exclusive license, with rights to sublicense, to market, promote, distribute, offer for sale and sell certain Medisulfone-based filtration products in a defined territory, while Nephros grants Medica an exclusive license under its intellectual property to make these products during the term.
In return, Nephros committed to minimum annual aggregate purchases from Medica of €4,976,000, €5,349,000, €5,750,000, €6,000,000 and €6,300,000 for the years 2026, 2027, 2028, 2029 and 2030, respectively. The agreement runs through December 31, 2030, and replaces a prior 2023 license and supply agreement that was terminated when this new contract was signed.
Nephros may terminate the agreement for convenience with 90 days’ written notice, while Medica can terminate for uncured monetary defaults, and either party can terminate for material breaches or specified insolvency events. The contract also includes customary representations, warranties and indemnification obligations.
Nephros (NEPH) Form 4: A director reported acquiring 1,622 shares of common stock on 11/10/2025 at $0, held directly following the transaction.
The reporting person also holds a stock option to buy 13,229 shares at $4.49, expiring 08/11/2035. The option vests as to 4,410 shares on 6/16/25, 4,410 shares on 6/16/26, and 4,409 shares on 6/16/27.
Nephros, Inc. (NEPH) filed a Form 4 showing insider activity. A director reported acquiring 8,036 shares of common stock on 11/10/2025 at $0, bringing direct beneficial ownership to 122,881 shares following the transaction. The filing also lists multiple outstanding stock options with various exercise prices and expirations, with examples including options exercisable at $5.5755 expiring 08/10/2028 and at $2.14 expiring 05/14/2034.
Nephros (NEPH) Form 4: A director reported acquiring 5,391 shares of common stock on 11/10/2025 at a price of $0. Following this transaction, the director beneficially owned 131,272 shares directly.
The filing also lists outstanding stock options: 7,323 options with a $2.14 exercise price expiring 05/14/2034 and 7,050 options with a $1.47 exercise price expiring 01/01/2035. The vesting schedules include 2,441 shares on each of 5/14/24, 5/14/25, and 5/14/26 for the first grant, and 2,350 shares on each of 1/1/25, 1/1/26, and 1/1/27 for the second.
Nephros (NEPH) reported strong Q3 2025 results, driven by higher programmatic activity and service growth. Net revenue rose to $4.764M (up 35% year over year), with gross margin steady at 61%. Operating income improved to $0.314M, and net income reached $0.337M (basic and diluted EPS $0.03).
For the nine months, revenue increased to $14.060M (up 37%), gross margin expanded to 63%, and the company swung to $1.132M in net income from a prior loss. Operating cash flow was $1.415M, lifting cash to $5.171M and working capital to $8.239M. SG&A and R&D rose with higher commissions, bonus accruals, and salaries, while interest income increased.
The company notes customer concentration (top accounts comprised 46% of Q3 revenue) and continues to remediate a previously identified revenue recognition control weakness under ASC 606. As of November 3, 2025, 10,626,683 common shares were outstanding.
Lisa Nettis, a director of Nephros Inc. (NEPH), acquired 13,229 stock options on 08/11/2025 with an exercise price of $4.49 per share. The options convert into 13,229 shares of common stock and have an expiration date of 08/11/2035.
The filing discloses a vesting schedule: 4,410 options vest on each of 6/16/2025 and 6/16/2026, and 4,409 vest on 6/16/2027. The Form 4 was executed by Edward Peilen as attorney-in-fact on 08/13/2025 and lists Nettis as a director.
Nephros, Inc. furnished a press release disclosing its second quarter 2025 financial results and included that press release as Exhibit 99.1 to this Form 8-K. The company explicitly stated the exhibit is furnished, not filed, and therefore is not subject to liability under Section 18 of the Exchange Act nor automatically incorporated by reference into other filings unless expressly stated. The report was signed on behalf of the registrant by the Chief Financial Officer.
FAQ
What is the current stock price of Nephros (NEPH)?
What is the market cap of Nephros (NEPH)?
